RATIONALE-302 Clinical Trial

FOR MEDICAL PRESS ONLY

Disclaimer: This asset is intended for use by U.S. media professionals only. TEVIMBRA® (tislelizumab-jsgr) may not be available in all countries or regions. Please visit your local country website for local information.

The RATIONALE-302 trial is a pivotal study designed to evaluate the safety and efficacy of TEVIMBRA when compared with investigator’s choice of chemotherapy as a second-line treatment for patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).

Globally, esophageal cancer (EC) is the sixth most common cause of cancer-related deaths, and ESCC is the most common histologic subtype, accounting for nearly 90% of ECs. EC is a rapidly fatal disease, and more than two-thirds of patients have advanced or metastatic disease at the time of diagnosis, with an expected five-year survival rate of less than 6% for those with distant metastases.

RATIONALE-302 TRIAL (NCT03430843)

Trial Design

- Randomized, open-label, Phase 3 study comparing the humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody TEVIMBRA with investigator’s choice of chemotherapy
- 512 patients were randomized from 132 research sites in 11 countries in Europe, Asia, and North America

Key Inclusion Criteria

- Histologically confirmed diagnosis of ESCC
- Tumor progression during or after first-line treatment for advanced unresectable or metastatic ESCC
- At least one measurable/evaluable lesion by RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 prior to randomization
- Adequate end organ function
- Receipt of two or more prior systemic treatments for advanced unresectable or metastatic ESCC
- History of gastrointestinal perforation and/or fistula or aorto-esophageal fistula within six months prior to randomization
- Apparent tumor invasion into organs located adjacent to the esophageal disease site (e.g., aorta or respiratory tract) at an increased risk of fistula in the study treatment assessed by investigator
- Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage
- Received prior therapies targeting PD-1 or programmed cell death ligand 1 (PD-L1)
- Prior malignancy active within the previous two years (exceptions include the tumor under investigation in this trial and locally recurring cancers that have undergone curative treatment such as resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast)

Key Exclusion Criteria

- Active brain or leptomeningeal metastasis
- Has active autoimmune disease or history of autoimmune diseases at high risk for relapse
- Known history of, or any evidence of, interstitial lung disease, non-infectious pneumonitis, pulmonary fibrosis diagnosed based on imaging or clinical findings, or uncontrolled systemic diseases, including diabetes, hypertension, acute lung diseases, etc.
- Known history of human immunodeficiency virus
- Has cardiovascular risk factors
- Pregnant or breastfeeding individual
512 patients were randomized and treated until disease progression, unacceptable toxicity, or withdrawal.

**Study Arms**

**Arm 1**
200 mg TEVIMBRA intravenously (IV) every three weeks (256 patients)

**Arm 2**
Investigator-chosen standard chemotherapy (ICC), which included paclitaxel, docetaxel, or irinotecan (256 patients)

**Key Endpoints**

**Primary Endpoint**
Overall survival (OS) in the intent-to-treat (ITT) group

**Main Secondary Endpoints**
- OS in the PD-L1-positive group
- Overall response rate (ORR)
- Progression-free survival (PFS)
- Duration of response (DoR)
- Health-Related Quality of Life (HRQoL)
- Incidence and severity of adverse events

**TRIAL RESULTS**

**Key Efficacy Findings**

The study met its primary endpoint in the ITT population with a statistically significant and clinically meaningful survival benefit for TEVIMBRA compared with chemotherapy.

**Median OS**
- TEVIMBRA: 8.6 months (95% CI: 7.5, 10.4)
- Chemotherapy: 6.3 months (95% CI: 5.3, 7.0)
- Hazard ratio (HR)=0.70 (95% CI: 0.57, 0.85); p=0.0001

**ORR**
- TEVIMBRA: 15.2% (95% CI: 11.1, 20.2)
- Chemotherapy: 6.6% (95% CI: 3.9, 10.4)

**DoR**
- TEVIMBRA: 10.3 months (95% CI: 6.5, 15.2)
- Chemotherapy: 6.3 months (95% CI: 2.8, 8.5)
Key Safety Findings

The safety profile of TEVIMBRA was favorable over chemotherapy.

The most common (≥20%) adverse reactions for TEVIMBRA, including laboratory abnormalities, were increased glucose, decreased hemoglobin, decreased lymphocytes, decreased sodium, decreased albumin, increased alkaline phosphatase, anemia, fatigue, increased aspartate aminotransferase (AST), musculoskeletal pain, decreased weight, increased alanine aminotransferase (ALT), and cough.

About TEVIMBRA® (tislelizumab-jsgr)

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages, helping to aid the body's immune cells to detect and fight tumors.

U.S. Indication and Important Safety Information for TEVIMBRA® (tislelizumab-jsgr)

TEVIMBRA (tislelizumab-jsgr), as a single agent, is indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Severe and Fatal Immune-Mediated Adverse Reactions

TEVIMBRA is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death receptor-1 (PD-1) or PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions.

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. Immune-mediated adverse reactions can occur at any time after starting treatment with a PD-1/PD-L1 blocking antibody. While immune-mediated adverse reactions usually manifest during treatment with PD-1/PD-L1 blocking antibodies, immune-mediated adverse reactions can also manifest after discontinuation of PD-1/PD-L1 blocking antibodies. Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated reactions.

Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of PD-1/PD-L1 blocking antibodies. Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.

Withhold or permanently discontinue TEVIMBRA depending on severity. In general, if TEVIMBRA requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroids.

Immune-Mediated Pneumonitis

TEVIMBRA can cause immune-mediated pneumonitis, which can be fatal. In patients treated with other PD-1/PD-L1 blocking antibodies, the incidence of pneumonitis is higher in patients who have received prior thoracic radiation.
IMPORTANT SAFETY INFORMATION

Immune-mediated pneumonitis occurred in 3.8\% (75/1972) of patients receiving TEVIMBRA, including fatal (0.2\%), Grade 4 (0.3\%), Grade 3 (1.4\%), and Grade 2 (1.7\%) adverse reactions. Pneumonitis led to permanent discontinuation of TEVIMBRA in 35 (1.8\%) patients and withholding of TEVIMBRA in 27 (1.4\%) patients.

Systemic corticosteroids were required in all patients with pneumonitis. Immune-mediated pneumonitis resolved in 47\% of the 75 patients. Of the 27 patients in whom TEVIMBRA was withheld for pneumonitis, 18 reintiated TEVIMBRA after symptom improvement; of these, 3 (17\%) patients had recurrence of pneumonitis.

Immune-Mediated Colitis

TEVIMBRA can cause immune-mediated colitis, which can be fatal. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis treated with PD-1/PD-L1 blocking antibodies. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies.

Immune-mediated colitis occurred in 0.9\% (17/1972) of patients receiving TEVIMBRA, including Grade 3 (0.4\%), and Grade 2 (0.5\%) adverse reactions. Colitis led to permanent discontinuation of TEVIMBRA in 2 (0.3\%) patients and withholding of TEVIMBRA in 10 (0.5\%) patients. All 17 patients received systemic corticosteroids. Twelve (71\%) of the 17 patients received high-dose systemic corticosteroids. Two (12\%) of the 17 patients received immunosuppressive treatment. Immune-mediated colitis resolved in 88\% of the 17 patients. Of the 10 patients in whom TEVIMBRA was withheld for colitis, 8 reintiated TEVIMBRA after symptom improvement; of these, 1 (13\%) patient had recurrence of colitis.

Immune-Mediated Hepatitis

TEVIMBRA can cause immune-mediated hepatitis, which can be fatal. Immune-mediated hepatitis occurred in 1.7\% (34/1972) of patients receiving TEVIMBRA, including fatal (0.1\%), Grade 4 (0.1\%), Grade 3 (1\%), and Grade 2 (0.6\%) adverse reactions. Immune-mediated hepatitis led to permanent discontinuation in 9 (0.5\%) patients and withholding of TEVIMBRA in 20 (1\%) patients. All patients received systemic corticosteroids. Twenty-nine (85\%) of the 34 patients received high-dose systemic corticosteroids. One patient (2.9\%) of the 34 patients received immunosuppressive treatment. Immune-mediated hepatitis resolved in 59\% of the 34 patients. Of the 20 patients in whom TEVIMBRA was withheld for hepatitis, 12 reintiated TEVIMBRA after symptom improvement; of these, 2 (17\%) patients had recurrence of hepatitis.

Immune-Mediated Endocrinopathies

Adrenal Insufficiency

TEVIMBRA can cause immune-mediated adrenal insufficiency. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold TEVIMBRA depending on severity.

Immune-mediated adrenal insufficiency occurred in 0.3\% (6/1972) of patients receiving TEVIMBRA, including Grade 4 (0.1\%), Grade 3 (0.1\%), and Grade 2 (0.2\%) adverse reactions. Adrenal insufficiency did not lead to permanent discontinuation of TEVIMBRA. TEVIMBRA was withheld in 5 out of the 6 patients. All 6 patients received systemic corticosteroids. Two (33\%) of the 6 patients received high-dose systemic corticosteroids. Adrenal insufficiency resolved in 17\% of the 6 patients.

Hyperphysis

TEVIMBRA can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as clinically indicated. Withhold or permanently discontinue TEVIMBRA depending on severity.

Hypophysitis/hypopituitarism occurred in 0.1\% (1/1972) of patients receiving TEVIMBRA, including a Grade 2 (0.1\%) adverse reaction. No TEVIMBRA treatment discontinuation or withholding was required.

Thyroid Disorders

TEVIMBRA can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue TEVIMBRA depending on severity.

Thyroiditis: Immune-mediated thyroiditis occurred in 0.4\% (7/1972) of patients receiving TEVIMBRA, including Grade 2 (0.3\%) adverse reactions. Thyroiditis did not lead to permanent discontinuation of TEVIMBRA. TEVIMBRA was withheld in 1 (0.1\%) patient. One (4\%) of the 7 patients received systemic corticosteroids. Thyroiditis resolved in 29\% of the 7 patients.

Hyperthyroidism: Immune-mediated hyperthyroidism occurred in 0.6\% (12/1972) of patients receiving TEVIMBRA, including Grade 3 (0.1\%), and Grade 2 (0.5\%) adverse reactions. Hyperthyroidism led to the permanent discontinuation of TEVIMBRA in 1 (0.1\%) patient and withholding of TEVIMBRA in 1 (0.1\%) patient. One (8\%) of the 12 patients received systemic corticosteroids. Hyperthyroidism resolved in 92\% of the 12 patients.

Hypothyroidism: Immune-mediated hypothyroidism occurred in 7\% (132/1972) of patients receiving TEVIMBRA, including Grade 4 (0.1\%) and Grade 2 (0.5\%) adverse reactions. TEVIMBRA was not permanently discontinued in any patient, while treatment was withheld in 6 (0.3\%) patients. Two (1.5\%) of the 132 patients received systemic corticosteroids. All 132 patients received hormone replacement therapy. Hypothyroidism resolved in 27\% of the 132 patients. The majority (86\%) of patients with hypothyroidism required long-term thyroid hormone replacement.

Type 1 Diabetes Mellitus, which can present with Diabetic Ketoadicosis

Type 1 diabetes mellitus has been reported with PD-1/PD-L1 blocking antibodies. Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold or permanently discontinue TEVIMBRA depending on severity.

Immune-Mediated Nephritis with Renal Dysfunction

TEVIMBRA can cause immune-mediated nephritis, which can be fatal. Immune-mediated nephritis with renal dysfunction occurred in 0.4\% (7/1972) of patients receiving TEVIMBRA, including Grade 4 (0.1\%), Grade 3 (0.1\%), and Grade 2 (0.2\%) adverse reactions. TEVIMBRA was permanently discontinued in 3 (0.2\%) patients and treatment was withheld in 3 (0.2\%) patients. All patients received systemic corticosteroids. Nephritis with renal dysfunction resolved in 57\% of the 7 patients. Of the 3 patients in whom TEVIMBRA was withheld for nephritis, 2 reintiated TEVIMBRA after symptom improvement and one patient had recurrence of nephritis.

Immune-Mediated Dermatologic Adverse Reactions

TEVIMBRA can cause immune-mediated rash or dermatitis. Cases of severe cutaneous adverse reactions (SCARs), including exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), have been reported, some with fatal outcome.
IMPORTANT SAFETY INFORMATION

Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-exfoliative rashes. Withhold or permanently discontinue TEVIMBRA depending on severity.

Immune-mediated dermatologic adverse reactions occurred in 1.2% (24/1972) of patients receiving TEVIMBRA, including Grade 4 (0.2%), Grade 3 (0.4%), and Grade 2 (0.4%) adverse reactions. Dermatologic adverse reactions led to permanent discontinuation of TEVIMBRA in 3 (0.2%) patients and withholding of TEVIMBRA in 9 (0.5%) patients. Twenty-three (96%) of the 24 patients received systemic corticosteroids. Immune-mediated skin reactions resolved in 58% of the 24 patients. Of the 9 patients in whom TEVIMBRA was withheld for dermatologic adverse reactions, 8 reinitiated TEVIMBRA after symptom improvement; of these, 2 (25%) patients had recurrence of immune-mediated rash.

Other Immune-Mediated Adverse Reactions

The following clinically significant immune-mediated adverse reactions have been reported with other PD-1/PD-L1 blocking antibodies, including severe or fatal cases.

Cardiac/Vascular: Vasculitis

Nervous System: Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barre syndrome, nerve paresis, autoimmune neuropathy.

Ocular: Uveitis, iritis, and other ocular inflammatory toxicities can occur. Some cases can be associated with retinal detachment. Various grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic corticosteroids. Immune-mediated skin reactions resolved in 58% of the 24 patients. Of the 9 patients in whom TEVIMBRA was withheld for dermatologic adverse reactions, 8 reinitiated TEVIMBRA after symptom improvement; of these, 2 (25%) patients had recurrence of immune-mediated rash.

Gastrointestinal: Pancreatitis including increases in serum amylase and lipase levels, gastritis, duodenitis

Musculoskeletal and Connective Tissue: Polymyositis, rhabdomyolysis and associated sequelae including renal failure

Endocrine: Hypoparathyroidism

Other (Hematologic/Immune): Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection, other transplant (including corneal graft) rejection

Infusion-Related Reactions

TEVIMBRA can cause severe or life-threatening infusion-related reactions. Infusion-related reactions occurred in 4.2% (83/1972) patients receiving TEVIMBRA, including Grade 3 or higher (0.3%) reactions. Monitor patients for signs and symptoms of infusion-related reactions. Slow the rate of infusion for mild (Grade 1) and interrupt the infusion for moderate (Grade 2) infusion-related reactions. For severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions, stop infusion and permanently discontinue TEVIMBRA.

Complications of Allogeneic HSCT

Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1/PD-L1 blocking antibody. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT.

Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a PD-1/PD-L1 blocking antibody prior to or after an allogeneic HSCT.

Embryo-Fetal Toxicity

Based on its mechanism of action, TEVIMBRA can cause fetal harm when administered to a pregnant woman. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death. Advise women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TEVIMBRA and for 4 months after the last dose.

ADVERSE REACTIONS

Permanent discontinuation of TEVIMBRA due to an adverse reaction occurred in 19% of patients. Adverse reactions which resulted in permanent discontinuation in ≥ 1% of patients were hemorrhage, pneumonitis (including pneumonitis and immune-mediated pneumonitis), and pneumonia.

Dosage interruptions of TEVIMBRA due to an adverse reaction occurred in 25% of patients. Adverse reactions which required dosage interruptions in ≥ 2% of patients were pneumonia, pneumonitis, and fatigue. The most common (≥ 20%) adverse reactions, including laboratory abnormalities, were increased glucose, decreased hemoglobin, decreased lymphocytes, decreased sodium, decreased albumin, increased alkaline phosphatase, anemia, fatigue, increased AST, musculoskeletal pain, decreased weight, increased ALT, and cough.

Please see full Prescribing Information including Medication Guide.

References:

iv. TEVIMBRA, U.S. Package Insert. BeiGene USA, Inc; 2024.